Biodesix (BDSX)
(Delayed Data from NSDQ)
$1.80 USD
+0.01 (0.56%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $1.79 -0.01 (-0.56%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Biodesix, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 26 | 43 | 33 | 62 | 5 |
Receivables | 8 | 5 | 4 | 15 | 5 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 5 | 7 | 9 | 2 |
Total Current Assets | 40 | 53 | 44 | 86 | 13 |
Net Property & Equipment | 28 | 6 | 4 | 3 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 23 | 25 | 27 | 28 | 30 |
Deposits & Other Assets | 7 | 6 | 2 | 3 | 0 |
Total Assets | 99 | 93 | 76 | 121 | 45 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 2 | 2 | 9 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 12 | 12 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 8 | 8 | 8 | 8 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 22 | 11 | 20 | 4 | 5 |
Total Current Liabilities | 33 | 23 | 29 | 32 | 23 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 35 | 25 | 10 | 16 | 24 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 19 | 17 | 32 | 30 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 194 |
Total Liabilities | 95 | 72 | 56 | 80 | 270 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 424 | 388 | 322 | 300 | 2 |
Retained Earnings | -420 | -367 | -302 | -259 | -227 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 5 | 21 | 20 | 41 | -225 |
Total Liabilities & Shareholder's Equity | 99 | 93 | 76 | 121 | 45 |
Total Common Equity | 5 | 21 | 20 | 41 | -225 |
Shares Outstanding | 90.40 | 77.60 | 27.00 | 26.50 | NA |
Book Value Per Share | 0.05 | 0.27 | 0.73 | 1.55 | 0.00 |
Fiscal Year End for Biodesix, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 42 | 11 | 26 | 20 | 17 |
Receivables | 10 | 10 | 8 | 6 | 4 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 7 | 6 | 3 | 4 |
Total Current Assets | 58 | 28 | 40 | 29 | 25 |
Net Property & Equipment | 28 | 29 | 28 | 25 | 19 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 22 | 22 | 23 | 23 | 24 |
Deposits & Other Assets | 7 | 6 | 7 | 7 | 7 |
Total Assets | 116 | 87 | 99 | 87 | 78 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 3 | 3 | 3 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 8 | 8 | 8 | 7 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 7 | 20 | 22 | 22 | 16 |
Total Current Liabilities | 18 | 31 | 33 | 33 | 28 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 36 | 36 | 35 | 25 | 25 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 6 | 13 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 80 | 93 | 95 | 88 | 85 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 480 | 428 | 424 | 409 | 392 |
Retained Earnings | -444 | -433 | -420 | -410 | -399 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 36 | -6 | 5 | -1 | -7 |
Total Liabilities & Shareholder's Equity | 116 | 87 | 99 | 87 | 78 |
Total Common Equity | 36 | -6 | 5 | -1 | -7 |
Shares Outstanding | 145.10 | 114.60 | 90.40 | 78.60 | 78.40 |
Book Value Per Share | 0.25 | -0.05 | 0.05 | -0.02 | -0.09 |